A COMPOSITION COMPRISING PICRORETINE DERIVATIVES THAT EXHIBIT THE HYPOLIPIDEMIC CHARACTER AND THE USE OF THIS COMPOSITION FOR THE TREATMENT OF HIGH CHOLESTEROL
Creators: name: Alkoclar, Erdal Can
Publisher: name: Zenodo
Year: 2020
Subjects: sTAR Protein Hypolipidemic BAR Antagonism

description: The invention relates to a composition formed for exhibiting hypolipidemic character. <strong>State of the Art</strong> Hypolipidemics are various types of medications used as the lipid-lowering agents in the treatment of the elevated lipid levels in the blood. They are also referred to as hypolipidemic drugs or antihyperlipidemic drugs. The lipid lowering medications may be categorized into several classes. They differ in terms of side effects and their actions on the cholesterol profile. Some reduce LDL cholesterol known as “bad cholesterol”, while others increase HDL cholesterol known as “good cholesterol”. In clinical use, the patient’s cholesterol level, cardiovascular risk status and the liver and kidney functions are checked in order to determine which drug the patient is to take, and these are assessed along with the risks and the benefits of the drug. According to the state of the art, the invention no. WO 2000/020410 entitled "Propanolamine derivatives substituted with heterocyclic compounds, their production, medicaments, use" relates to heterocyclically substituted propanolamine derivatives and their pharmaceutically acceptable salts and physiologically functional derivatives. The invention describes compounds of formula (I), wherein the radicals have the meanings thus cited, as well as their physiologically acceptable salts, physiologically functional derivatives and methods for the production thereof. The compounds are suitable as, for example, hypolipidemic agents. Further, the invention no. EP1414439B1 entitled "Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine" provides methods for the preparation of the novel compounds defined in the general formula (I), their tautomeric forms, their derivatives, their analogs, their stereoisomers, their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates. This invention also relates to the process for preparing such compounds, a composition containing such a compound and the use of such a compound and composition in medicine. The compounds lower the triglyceride levels in the blood and may be useful in the treatment of obesity, hyperlipidemia, hypercholesteremia, syndrome X and diabetes. Further, the invention no. WO 2000/020437 entitled "Propanolamine derivatives linked with the bile acid used for treating disorders of the lipid metabolism" relates to the propanolamine derivatives linked with the bile acids, the methods for preparing the same, the medicaments comprising these compositions and the uses thereof. The invention relates to substituted propanolamine derivatives and their pharmaceutically acceptable salts and physiologically functional derivatives. The invention relates to compounds of formula (I), wherein the radicals have the defined meanings, as well as their physiologically acceptable salts, physiologically acceptable derivatives and methods for their production. The compounds are suitable, for example, as hypolipidemic agents. As a result, the presence of the need for a composition for exhibiting hypolipidemic character and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art. <strong>Object of the Invention</strong> In order to eliminate the disadvantages of the state of the art, an object of the invention is to establish BAR antagonistic function. Another object of the invention is to trigger an increase in the CYP7A1 expression. Another object of the invention is to trigger an increase in the expression of sTAR protein. In order to achieve the aforesaid advantages, the invention is a composition for exhibiting hypolipidemic character and for treating high cholesterol, said composition being obtained by the components selected from the group comprising <strong>3,20-dimethyl-1,2,21,22-tetradehydro-2,3,20,21-picroretine, 4,20-dimethyl-1,2,21,22-tetradehydro-2,3,20,21-picroretine </strong>that are used individually or in combinations. The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration.